Identification of candidate metabolite biomarkers for metabolic syndrome and its five components in population-based human cohorts.
Amino acids
BCAAs
Cardiovascular disease
Hyperglycemia
Hypertension
Lysophosphatidylcholines
Metabolic syndrome
Metabolomics
Obesity
Phosphatidylcholines
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
16 06 2023
16 06 2023
Historique:
received:
03
04
2023
accepted:
20
05
2023
medline:
19
6
2023
pubmed:
17
6
2023
entrez:
16
6
2023
Statut:
epublish
Résumé
Metabolic Syndrome (MetS) is characterized by risk factors such as abdominal obesity, hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), hypertension, and hyperglycemia, which contribute to the development of cardiovascular disease and type 2 diabetes. Here, we aim to identify candidate metabolite biomarkers of MetS and its associated risk factors to better understand the complex interplay of underlying signaling pathways. We quantified serum samples of the KORA F4 study participants (N = 2815) and analyzed 121 metabolites. Multiple regression models adjusted for clinical and lifestyle covariates were used to identify metabolites that were Bonferroni significantly associated with MetS. These findings were replicated in the SHIP-TREND-0 study (N = 988) and further analyzed for the association of replicated metabolites with the five components of MetS. Database-driven networks of the identified metabolites and their interacting enzymes were also constructed. We identified and replicated 56 MetS-specific metabolites: 13 were positively associated (e.g., Val, Leu/Ile, Phe, and Tyr), and 43 were negatively associated (e.g., Gly, Ser, and 40 lipids). Moreover, the majority (89%) and minority (23%) of MetS-specific metabolites were associated with low HDL-C and hypertension, respectively. One lipid, lysoPC a C18:2, was negatively associated with MetS and all of its five components, indicating that individuals with MetS and each of the risk factors had lower concentrations of lysoPC a C18:2 compared to corresponding controls. Our metabolic networks elucidated these observations by revealing impaired catabolism of branched-chain and aromatic amino acids, as well as accelerated Gly catabolism. Our identified candidate metabolite biomarkers are associated with the pathophysiology of MetS and its risk factors. They could facilitate the development of therapeutic strategies to prevent type 2 diabetes and cardiovascular disease. For instance, elevated levels of lysoPC a C18:2 may protect MetS and its five risk components. More in-depth studies are necessary to determine the mechanism of key metabolites in the MetS pathophysiology.
Sections du résumé
BACKGROUND
Metabolic Syndrome (MetS) is characterized by risk factors such as abdominal obesity, hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), hypertension, and hyperglycemia, which contribute to the development of cardiovascular disease and type 2 diabetes. Here, we aim to identify candidate metabolite biomarkers of MetS and its associated risk factors to better understand the complex interplay of underlying signaling pathways.
METHODS
We quantified serum samples of the KORA F4 study participants (N = 2815) and analyzed 121 metabolites. Multiple regression models adjusted for clinical and lifestyle covariates were used to identify metabolites that were Bonferroni significantly associated with MetS. These findings were replicated in the SHIP-TREND-0 study (N = 988) and further analyzed for the association of replicated metabolites with the five components of MetS. Database-driven networks of the identified metabolites and their interacting enzymes were also constructed.
RESULTS
We identified and replicated 56 MetS-specific metabolites: 13 were positively associated (e.g., Val, Leu/Ile, Phe, and Tyr), and 43 were negatively associated (e.g., Gly, Ser, and 40 lipids). Moreover, the majority (89%) and minority (23%) of MetS-specific metabolites were associated with low HDL-C and hypertension, respectively. One lipid, lysoPC a C18:2, was negatively associated with MetS and all of its five components, indicating that individuals with MetS and each of the risk factors had lower concentrations of lysoPC a C18:2 compared to corresponding controls. Our metabolic networks elucidated these observations by revealing impaired catabolism of branched-chain and aromatic amino acids, as well as accelerated Gly catabolism.
CONCLUSION
Our identified candidate metabolite biomarkers are associated with the pathophysiology of MetS and its risk factors. They could facilitate the development of therapeutic strategies to prevent type 2 diabetes and cardiovascular disease. For instance, elevated levels of lysoPC a C18:2 may protect MetS and its five risk components. More in-depth studies are necessary to determine the mechanism of key metabolites in the MetS pathophysiology.
Identifiants
pubmed: 37328862
doi: 10.1186/s12933-023-01862-z
pii: 10.1186/s12933-023-01862-z
pmc: PMC10276453
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
141Informations de copyright
© 2023. The Author(s).
Références
Heart. 2017 Aug;103(16):1278-1285
pubmed: 28255100
PLoS Med. 2006 Feb;3(2):e22
pubmed: 16354105
BMC Med. 2013 Mar 07;11:63
pubmed: 23497300
Neurogastroenterol Motil. 2019 Mar;31(3):e13511
pubmed: 30444067
Can J Physiol Pharmacol. 2013 Oct;91(10):855-60
pubmed: 24144057
BMC Med. 2013 Mar 04;11:60
pubmed: 23497222
Bioinform Biol Insights. 2020 Jan 31;14:1177932219899051
pubmed: 32076369
Int J Epidemiol. 2022 Dec 13;51(6):e372-e383
pubmed: 35348705
Curr Hypertens Rep. 2018 Feb 26;20(2):12
pubmed: 29480368
Aging Cell. 2012 Dec;11(6):960-7
pubmed: 22834969
Diabetes. 2020 Dec;69(12):2756-2765
pubmed: 33024004
Cell Metab. 2012 May 2;15(5):606-14
pubmed: 22560213
Brief Bioinform. 2022 Mar 10;23(2):
pubmed: 34981111
Diabet Med. 2010 Oct;27(10):1116-23
pubmed: 20854378
J Lipid Res. 2011 Jun;52(6):1234-1246
pubmed: 21447485
Int J Epidemiol. 2011 Apr;40(2):294-307
pubmed: 20167617
Clin Sci (Lond). 2014 Jan 1;126(1):19-29
pubmed: 23742196
Int J Mol Sci. 2021 Jun 25;22(13):
pubmed: 34202257
Front Genet. 2021 Jan 25;12:625120
pubmed: 33569080
Amino Acids. 2021 Feb;53(2):149-157
pubmed: 33398528
Nutr Metab Cardiovasc Dis. 2017 Nov;27(11):1021-1030
pubmed: 28958693
Metabolites. 2021 Mar 24;11(4):
pubmed: 33805221
Int J Sports Med. 2021 Mar;42(3):199-214
pubmed: 33075830
Pharmaceuticals (Basel). 2021 Feb 26;14(3):
pubmed: 33652666
Adv Nutr. 2011 Nov;2(6):445-56
pubmed: 22332087
Mol Psychiatry. 2021 Dec;26(12):7372-7383
pubmed: 34088979
Diabetes. 2013 Feb;62(2):639-48
pubmed: 23043162
Mol Syst Biol. 2012;8:615
pubmed: 23010998
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Cardiovasc Diabetol. 2021 May 20;20(1):111
pubmed: 34016094
Biochim Biophys Acta. 2012 May;1821(5):754-61
pubmed: 21979151
Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1552-63
pubmed: 17925455
Genome Biol. 2012 Jul 18;13(7):R62
pubmed: 22809392
Annu Rev Physiol. 2019 Feb 10;81:165-188
pubmed: 30379616
Biochim Biophys Acta Mol Basis Dis. 2018 Feb;1864(2):488-498
pubmed: 29158183
Environ Int. 2022 Dec;170:107632
pubmed: 36402035
Nucleic Acids Res. 2022 Jan 7;50(D1):D622-D631
pubmed: 34986597
Sci Rep. 2020 Feb 26;10(1):3483
pubmed: 32103083
J Diabetes Metab Disord. 2021 Nov 26;21(1):889-917
pubmed: 35673462
Nutrition. 2021 Mar;83:111082
pubmed: 33360505
Cell Metab. 2017 Jan 10;25(1):43-56
pubmed: 28094011
J Lipid Res. 2005 Jul;46(7):1517-25
pubmed: 15834125
Med Sci Monit. 2019 Aug 25;25:6383-6390
pubmed: 31446436
Metabolites. 2021 Apr 13;11(4):
pubmed: 33924347
FASEB J. 1993 Jun;7(9):791-800
pubmed: 8330686
Expert Rev Cardiovasc Ther. 2017 Dec;15(12):913-921
pubmed: 29183206
PLoS One. 2012;7(6):e40009
pubmed: 22761945
Aging Dis. 2015 Oct 01;6(5):390-9
pubmed: 26425393
Cardiovasc Diabetol. 2022 Dec 23;21(1):288
pubmed: 36564831
J Diabetes Complications. 2018 Aug;32(8):791-794
pubmed: 29895440
J Diabetes Complications. 2018 May;32(5):465-469
pubmed: 29559272
Transl Psychiatry. 2013 Jul 02;3:e276
pubmed: 23820610
PLoS One. 2016 Jan 25;11(1):e0147483
pubmed: 26808524
Eur J Endocrinol. 2004 Oct;151(4):483-9
pubmed: 15476449
Amino Acids. 2020 Oct;52(10):1413-1423
pubmed: 33057941
Curr Opin Struct Biol. 2015 Dec;35:1-6
pubmed: 26241318
Cell Biol Toxicol. 2019 Oct;35(5):457-470
pubmed: 30721374
PeerJ. 2018 Aug 31;6:e5410
pubmed: 30186675
Comput Struct Biotechnol J. 2021 May 12;19:3034-3041
pubmed: 34136101
Int J Mol Sci. 2019 Mar 06;20(5):
pubmed: 30845751
J Endocrinol Invest. 2022 May;45(5):927-939
pubmed: 35013990
Nutrients. 2017 Feb 10;9(2):
pubmed: 28208582
J Investig Med. 2016 Aug;64(6):1082-6
pubmed: 27194746
Nat Rev Endocrinol. 2014 May;10(5):293-302
pubmed: 24663222
PLoS Genet. 2011 Aug;7(8):e1002215
pubmed: 21852955
Obes Facts. 2012;5(5):660-70
pubmed: 23108202
Diabet Med. 2010 Mar;27(3):360-2
pubmed: 20536501